NCT02352025View on ClinicalTrials.gov

S-equol in Women With Triple Negative Breast Cancer

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

39

Participants

Timeline

Start Date

April 15, 2015

Primary Completion Date

April 10, 2019

Study Completion Date

June 30, 2020

Conditions
Breast Cancer
Interventions
DRUG

S-equol

S-equol should be administered orally, twice daily (12 hours apart), preferably on an empty stomach with a glass of water. Tablets should be swallowed whole.

Trial Locations (1)

78229

CTRC (Cancer Therapy and Research Center) at UTHSCSA, San Antonio

All Listed Sponsors
lead

The University of Texas Health Science Center at San Antonio

OTHER

NCT02352025 - S-equol in Women With Triple Negative Breast Cancer | Biotech Hunter | Biotech Hunter